8-K: Aptevo Therapeutics Secures $8 Million in Public Offering, Reports Strong Clinical Data for AML Drug Mipletamig and Expands Oncology Pipeline

Aptevo Therapeutics Inc. has successfully closed an $8 million public offering to fund clinical programs and general corporate purposes, while also announcing compelling clinical data for its lead AML therapeutic, mipletamig, and expanding its CD3-directed oncology pipeline.

Summary

• Aptevo Therapeutics Inc. completed a registered direct offering, raising approximately $8 million in gross proceeds and $7.45 million in net proceeds.
• The offering included the sale of 2,105,000 shares of common stock, pre-funded warrants for up to 360,000 shares, and common warrants for up to 12,325,000 shares.
• The combined purchase price for one share of common stock and accompanying common warrants was $3.25, while pre-funded warrants with common warrants were priced at $3.249.
• Common Warrants have an exercise price of $3.25 per share, are exercisable upon stockholder approval, and expire five years from that approval date, with a floor price of $0.65.
• Pre-funded Warrants are immediately exercisable at a nominal price of $0.001 per share.
• The company intends to use the net proceeds for working capital, funding clinical programs, and general corporate purposes, including further development of product candidates.
• New clinical data from the Phase 1b/2 RAINIER trial for mipletamig in frontline Acute Myeloid Leukemia (AML) patients unfit for intensive chemotherapy showed an 85% remission rate (CR/CRi) across two trials.
• No cytokine release syndrome (CRS) was observed in mipletamig cohorts 1 or 2, indicating a strong safety profile.
• One patient with a poor prognosis genetic biomarker (TP53) achieved complete remission (CR) and successfully received a transplant, a rare outcome in this patient population.
• Aptevo announced the addition of APVO455, a Nectin-4 x CD3 bispecific T-cell engager, to its preclinical pipeline, targeting various solid tumors.
• The company's CD3-directed pipeline now includes mipletamig (AML), APVO442 (prostate cancer), and APVO455 (solid tumors), all utilizing the CRIS-7 derived CD3 binding domain designed for low cytokine release.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to the successful capital raise, which provides financial stability for ongoing operations and clinical development. The reported clinical data for mipletamig in AML is exceptionally strong, showing high remission rates and a favorable safety profile compared to benchmarks. The expansion of the preclinical pipeline further enhances the company's long-term prospects. While there are inherent risks in clinical development and the common warrants' value is contingent on stockholder approval, the overall tone and factual disclosures indicate significant positive momentum.

Positives

• Successful completion of an $8 million public offering provides crucial capital for ongoing clinical development and general corporate purposes.
• Mipletamig, the lead therapeutic candidate, demonstrated a compelling 85% remission rate (CR/CRi) in evaluable frontline AML patients, significantly exceeding competitor study results.
• The mipletamig trial showed a strong safety profile with no cytokine release syndrome (CRS) observed in the first two cohorts, addressing a key concern with T-cell engagers.
• A patient with a poor prognosis genetic biomarker (TP53) achieved complete remission and proceeded to transplant, highlighting mipletamig's potential in difficult-to-treat AML.
• The expansion of the CD3-directed pipeline with APVO455 and APVO442, leveraging the unique CRIS-7 binding domain, suggests a robust and differentiated development strategy for both hematologic and solid tumors.
• The company's commitment to obtaining stockholder approval for the common warrants ensures compliance with Nasdaq rules and potential future capital infusion upon exercise.

Negatives

• The value of the common warrants is contingent on obtaining stockholder approval, and if not obtained, these warrants will have no value.
• The offering results in dilution of the outstanding shares of common stock, which could be substantial under certain market conditions.

Risks

• Actual results may differ materially from forward-looking statements due to a deterioration in Aptevo's business or prospects.
• Further assessment of preliminary or interim data or different results from later clinical trials could alter current positive findings.
• Adverse events, unanticipated problems, or unexpected safety issues observed during clinical trials could negatively impact drug development.
• Changes in regulatory, social, macroeconomic, and political conditions may affect operations and financial performance.
• Uncertainties inherent in preliminary or interim data being predictive of the results of later-stage clinical trials.
• Challenges related to patient initiation, enrollment, maintenance, and completion of clinical trials.
• The trial design for mipletamig, which includes combination therapies, may make it difficult to accurately ascertain the specific benefits attributable to mipletamig.
• Uncertainties regarding the timing and steps required in the regulatory review process and the likelihood of obtaining regulatory approvals.
• The impact of competitive products in the immuno-oncology and AML treatment landscape.
• The company's ability to enter into agreements with strategic partners or raise additional funds on acceptable terms or at all.
• Business or economic disruptions due to catastrophes, natural disasters, public health crises, or geopolitical risks (e.g., wars in Russia-Ukraine, Israel-Hamas, Israel-Iran).
• Macroeconomic conditions such as economic uncertainty, imposition of tariffs, rising inflation and interest rates, continued market volatility, and decreased consumer confidence could adversely affect the company.

Future Outlook

Aptevo Therapeutics plans to use the net proceeds from the offering to continue the clinical development of its product candidates, including mipletamig in the RAINIER trial for AML, and for general corporate purposes. The company anticipates further expanding its CD3 suite of drug candidates, with preclinical studies ongoing for APVO442 (prostate cancer) and the newly added APVO455 (Nectin-4+ solid tumors). The company aims to continue demonstrating compelling clinical activity and a strong safety profile for its therapeutic candidates, with the goal of improving treatment outcomes and transforming the lives of cancer patients.

Management Comments

• "These results deepen our conviction in mipletamig’s ability to elevate treatment outcomes for frontline AML patients who are not candidates for intensive chemotherapy. This outstanding remission rate, combined with a compelling safety profile—no CRS reported in the first two cohorts, reinforces mipletamig’s potential to meaningfully enhance the venetoclax/azacitidine backbone."
• "We believe our success with mipletamig is a direct reflection of our unique CD3 engineering strategy. We are the only ones using the CRIS-7 binding domain. We did this purposefully, to mitigate cytokine-related toxicity while preserving anti-cancer activity. This innovation not only differentiates mipletamig but represents a core advantage we intend to carry forward across our CD3 pipeline, including with our preclinical candidate, APVO442, for prostate cancer."
• "With APVO455, we are rounding out a purposefully designed CD3 product suite that reflects both scientific rigor and clinical learning. Compelling mipletamig clinical results, where we have treated more than 100 patients across three trials, give us confidence that CRIS-7 is a critical differentiator. Our molecules behave predictably, drive selective activation and are emerging from a shared design strategy grounded in real-world human data."
• "Ultimately, this design choice has yielded a compelling safety profile in the clinic, as seen with mipletamig, and supports broader application across indications where tolerability remains a barrier to effective T-cell engagement."

Industry Context

The announcement positions Aptevo Therapeutics as an active player in the immuno-oncology space, particularly in the development of bispecific antibodies. The focus on Acute Myeloid Leukemia (AML) addresses a critical unmet need, especially for patients unfit for intensive chemotherapy, where treatment options are limited and outcomes are generally poor. The company's emphasis on its proprietary ADAPTIR and ADAPTIR-FLEX platform technologies and the unique CRIS-7 derived CD3 binding domain aims to differentiate its candidates by mitigating cytokine-related toxicity, a common challenge with T-cell engagers. The expansion into solid tumors with APVO442 and APVO455 indicates a broader strategic ambition within the oncology market, targeting highly expressed antigens like Nectin-4 and PSMA.

Comparison to Industry Standards

• Mipletamig's 85% remission rate (CR/CRi) in evaluable frontline AML patients across two trials is stated to significantly exceed results from competitor studies, specifically mentioning the Viale A trial.
• The Viale A trial evaluated venetoclax and azacitidine (ven/aza) as a doublet therapy, serving as a benchmark against which mipletamig's triplet therapy (mipletamig + ven/aza) is compared favorably.
• The absence of Cytokine Release Syndrome (CRS) in mipletamig cohorts 1 and 2 is highlighted as a compelling safety advantage, differentiating it from other T-cell engagers that often face CRS challenges.
• The successful transplant of a TP53-mutated AML patient (a poor prognosis biomarker) after achieving CR with mipletamig is presented as a rare and favorable outcome, suggesting superior efficacy in a challenging patient subgroup compared to standard approaches.

Corporate Governance

Stakeholder Impact

• **Shareholders**: Experience dilution from the issuance of new common stock and warrants. However, the capital raise provides funding for clinical programs, which could lead to increased shareholder value if successful. The value of common warrants held by investors is contingent on stockholder approval.
• **Investors (Purchasers in Offering)**: Acquire common stock, pre-funded warrants, and common warrants, providing immediate and potential future equity participation. Their investment supports the company's clinical development.
• **Employees**: Continued funding for clinical programs supports ongoing research and development activities, potentially ensuring job stability and progress in their work.
• **Patients (Acute Myeloid Leukemia)**: The positive clinical data for mipletamig suggests a promising new therapeutic option, particularly for those unfit for intensive chemotherapy, potentially improving treatment outcomes and quality of life.
• **Regulatory Authorities (SEC, Nasdaq)**: The filing demonstrates compliance with SEC reporting requirements and Nasdaq listing rules, including the need for stockholder approval for warrant exercise.

Next Steps

• Aptevo will use net proceeds for continued clinical development of product candidates and general corporate purposes.
• The company will use reasonable best efforts to hold a special meeting of stockholders on or prior to sixty (60) days after the Closing Date to obtain Stockholder Approval for the exercise of the Common Warrants.
• If Stockholder Approval is not obtained at the first meeting, the Company will call subsequent meetings every sixty (60) days until approval is received or warrants are no longer outstanding.
• Continued enrollment and dose optimization in the Phase 1b/2 RAINIER trial for mipletamig, with Cohort 3 nearing full enrollment.
• Further preclinical development of APVO442 for prostate cancer and APVO455 for Nectin-4+ solid tumors.
• Potential future expansion of the CD3-directed pipeline.

Key Dates

Recommendation

Keywords

Aptevo Therapeutics, APVO, SEC Filing, 8-K, Public Offering, Common Stock, Warrants, Pre-funded Warrants, Capital Raise, Clinical-stage biotechnology, Immuno-oncology, ADAPTIR platform, ADAPTIR-FLEX platform, Mipletamig, RAINIER trial, Acute Myeloid Leukemia, AML, CD123 x CD3 bispecific antibody, Venetoclax, Azacitidine, Remission rate, Cytokine Release Syndrome, CRS, CRIS-7 binding domain, APVO455, Nectin-4 x CD3 bispecific, Solid tumors, APVO442, PSMA x CD3, Prostate cancer, ALG.APV-527, 4-1BB agonist, Orphan drug designation, Nasdaq Capital Market, Stockholder Approval